Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

nce, noted, "The early data from our antiviral program designed to test the potential of our PS-targeting antibodies to prevent and treat viral hemorrhagic fevers is very encouraging, and we are pleased to have the opportunity to present our findings at this major meeting of our biodefense peers. Results to date are confirming that our PS-targeting antibodies may have broad spectrum potential against multiple viruses, which could make them valuable against both hemorrhagic fever viruses and other biodefense threats. Further efficacy studies are already underway and we look forward to reporting on our progress as we continue to advance this important program."

Researchers also reported that studies are in progress to determine the pharmacokinetics and efficacy of PS-targeting antibodies in additional VHF infection models, as well as to develop lyophilized formulations suitable for an extended shelf life under a variety of storage and shipping conditions. In addition, Peregrine is developing a second-generation, fully human PS-targeting antibody as part of its federally funded antiviral program efforts.

"These positive initial efficacy data after administration of only a single dose is an early confirmation of the potential of our anti-PS antibodies as broad-spectrum therapeutics for VHF," said Steven W. King, president and CEO of Peregrine. "They also reflect the excellent progress being achieved by our multi-institutional project team. This first public presentation of data from our ongoing federally funded program is also consistent with our extensive preclinical and clinical experience showing the broad-spectrum antiviral potential of our PS-targeting technology platform and we look forward to sharing more results from the studies as further progress is made."

Under a major biodefense initiative, bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers un
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... energy use, increased its investment in Green Chemistry and ... the world last year, the Company announced Monday in ... Science Changed the World? The report ... honors for being a responsible corporate citizen, including recognition ...
(Date:7/29/2014)... July 29, 2014 G-CON Manufacturing Inc., ... cleanrooms, today announced a new leadership appointment designed to ... States and abroad. , Maik Jornitz, Chief Operating ... company’s President charged with leading the pioneering company through ... enter this stage of development and look forward to ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
Breaking Biology Technology:TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2
... 30, 2011 Merrimack Pharmaceuticals, Inc. announced today ... an oligoclonal therapeutic consisting of a mixture of ... encapsulation of irinotecan, at the 14th World Conference ... 7, 2011, in Amsterdam, The Netherlands. ...
... 29, 2011 Dendreon Corporation (Nasdaq: ... and Drug Administration (FDA) approved its Los Angeles cancer ... increase the availability of PROVENGE ® (sipuleucel-T) across ... with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone ...
... Olive Branch Fund: A Thisbe and Noah Scott Legacy, ... today announced its first funding award to Kevin Eggan, ... at Harvard University.  The award will support Dr. Eggan,s ... that affect it.  Dr. Eggan is a leading researcher ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
(Date:7/29/2014)... book that brings together two of the major disciplines ... of insect fossils through stunning photographs and unique illustrations. ... E Jepson, details the incredible preservation and diversity of ... for what these remarkable fossils can tell us about ... of our planet. Like the mosquito in Jurassic Park, ...
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... States have a circulatory problem of the legs called ... even require surgery in serious cases. This disease can ... limb amputation. , At The University of Texas Health ... a non-surgical preventative treatment in a mouse model of ... circulation. Their proof-of-concept study appears in the journal ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... pollution from power plants and automobiles is destroying the ... pollinating insects to follow scent trails to their source, ... partially explain why wild populations of some pollinators, particularly ... declining in several areas of the world, including California ...
... may be so old that dinosaurs once lumbered along its ... of Colorado at Boulder and the California Institute of Technology. ... to show the Grand Canyon may have formed more than ... 40 million to 50 million years. The researchers gathered ...
... Researchers from all over the world have been ... mouth and saliva cells to carry out the DNA analysis., ... (director of the Laboratory of Genetic Identification of the ... by the court in cases of paternity tests, for the ...
Cached Biology News:Flowers' fragrance diminished by air pollution, University of Virginia study indicates 2Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3Fraud attempt in a paternity test modifies action protocol in DNA tests 2
... by John M. Walker (1996) • ... analytical techniques for studying proteins and ... contains detailed, step-by-step instruction, timesaving troubleshooting ... comprehensive lists of reagents and suppliers. ...
...
ANTI S. ENT TOX BC2D...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
Biology Products: